Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
R. William DePaolo, PhD
Associate Professor & Director, Center for Microbiome Sciences & Therapeutics (CMiST)

Dr. William DePaolo, Will, is an Associate Professor of Medicine at the University of Washington Medical Center and is the recipient of the Lynn M. and Michael D. Garvey endowed chair in Gastroenterology. He was named Director of the Center for Microbiome Sciences & Therapeutics (CMiST). CMiST will serve as a beacon for investigators, clinicians and patients interested in the human microbiome, and will offer a number of Innovation Services, facilitate collaboration and exploration through workshops and seminar series, and work alongside clinicians to develop and test microbiome-derived therapeutics.

In 2004, Will received his PhD in Immunology & Microbial Pathogenesis from the Feinberg School of Medicine of Northwestern University. Will then completed his postdoctoral training at the University of Chicago where he investigated the molecular pathogenesis of Yersinia pestis, the bacterium that causes bubonic plague, while concurrently developing projects investigating immune-modulation within the intestine. In 2011, Will joined the faculty at University of Southern California as an Assistant Professor in the Department of Molecular Microbiology and Immunology. Will combines his interdisciplinary training to investigate the contribution of our 100 trillion gut bacteria (or microbiome) to inflammatory diseases and to develop strategies aimed at manipulating this vast community. Will's current research extends across scientific disciplines and clinical diseases such as obesity, colon cancer, inflammatory bowel disease and enteric pathogens.

DePaolo Lab | CMiST

Recent Publications
Displaying 20 Most Recent Publications from PubMed

May 2018. Innate Recognition of the Microbiota by TLR1 Promotes Epithelial Homeostasis and Prevents Chronic Inflammation. Kamdar K, Johnson AMF, Chac D, Myers K, Kulur V, Truevillian K, DePaolo RW. J Immunol. 2018 May 23. pii: ji1701216. doi: 10.4049/jimmunol.1701216. [Epub ahead of print]

February 2018. Infectious Scarring: Setting the Trigger for Intestinal Inflammation. Johnson AMF, DePaolo RW. Cell Host Microbe. 2018 Feb 14;23(2):154-156. doi: 10.1016/j.chom.2018.01.017.

September 2017. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ. Int J Cancer. 2017 Sep 15;141(6):1222-1230. doi: 10.1002/ijc.30810. Epub 2017 Jun 21.

June 2017. Window-of-opportunity: neonatal gut microbiota and atopy. Johnson AMF, DePaolo RW. Hepatobiliary Surg Nutr. 2017 Jun;6(3):190-192. doi: 10.21037/hbsn.2017.03.05.

January 2016. Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease. Kamdar K, Khakpour S, Chen J, Leone V, Brulc J, Mangatu T, Antonopoulos DA, Chang EB, Kahn SA, Kirschner BS, Young G, DePaolo RW. Cell Host Microbe. 2016 Jan 13;19(1):21-31. doi: 10.1016/j.chom.2015.12.006.

March 2011. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. DePaolo RW, Abadie V, Tang F, Fehlner-Peach H, Hall JA, Wang W, Marietta EV, Kasarda DD, Waldmann TA, Murray JA, Semrad C, Kupfer SS, Belkaid Y, Guandalini S, Jabri B. Nature. 2011 Mar 10;471(7337):220-4. doi: 10.1038/nature09849. Epub 2011 Feb 9.

August 2009. Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis. Elhofy A, Depaolo RW, Lira SA, Lukacs NW, Karpus WJ. J Neuroimmunol. 2009 Aug 18;213(1-2):91-9. doi: 10.1016/j.jneuroim.2009.05.011. Epub 2009 Jun 17.

October 2008. Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis. Depaolo RW, Tang F, Kim I, Han M, Levin N, Ciletti N, Lin A, Anderson D, Schneewind O, Jabri B. Cell Host Microbe. 2008 Oct 16;4(4):350-61. doi: 10.1016/j.chom.2008.09.004.

August 2006. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. DeBord KL, Anderson DM, Marketon MM, Overheim KA, DePaolo RW, Ciletti NA, Jabri B, Schneewind O. Infect Immun. 2006 Aug;74(8):4910-4.

October 2005. The chemokine CCL2 is required for control of murine gastric Salmonella enterica infection. Depaolo RW, Lathan R, Rollins BJ, Karpus WJ. Infect Immun. 2005 Oct;73(10):6514-22.

September 2005. Plague bacteria target immune cells during infection. Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O. Science. 2005 Sep 9;309(5741):1739-41. Epub 2005 Jul 28.

August 2005. LcrV plague vaccine with altered immunomodulatory properties. Overheim KA, Depaolo RW, Debord KL, Morrin EM, Anderson DM, Green NM, Brubaker RR, Jabri B, Schneewind O. Infect Immun. 2005 Aug;73(8):5152-9.

July 2004. CCR5 regulates high dose oral tolerance by modulating CC chemokine ligand 2 levels in the GALT. DePaolo RW, Lathan R, Karpus WJ. J Immunol. 2004 Jul 1;173(1):314-20.

October 2003. CC chemokine ligand 2 and its receptor regulate mucosal production of IL-12 and TGF-beta in high dose oral tolerance. DePaolo RW, Rollins BJ, Kuziel W, Karpus WJ. J Immunol. 2003 Oct 1;171(7):3560-7.

Contact Info

Post-doctoral Fellow, University of Chicago, 2004-2006

PhD Immunology and Microbiology, Northwestern Medical School, 2004

Fellowship, Memorial Sloan Kettering Cancer Center, 1997-1999

Bachelor of Science, Neuroscience, Bates College,1999

©2016-2018 University of Washington Division of Gastroenterology
1959 NE Pacific St., Box 356424, Seattle, WA 98195-6424
Contact Us | Privacy | Terms | Copyright & Disclaimer